Candidate Compounds Covid19

Aus coViki
Wechseln zu: Navigation, Suche

coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.

current items will be put into the subsections.






32628145 2020. Blocking angiotensin earlier with RAS blockers, statins, and heparin in high-risk COVID-19 patients: Is the remedy here?
32634024 2020. How to Quantify and Interpret Treatment Effects in Comparative Clinical Studies of COVID-19.
32646061 2020. Could Ergothioneine Aid in the Treatment of Coronavirus Patients?
32638906 2020. Controle do Intervalo QT para Prevencao de Torsades de Pointes Durante uso de Hidroxicloroquina e/ou Azitromicina em Pacientes com COVID 19.
32645994 2020. Ten-Year Research Update Review: Antiviral Activities from Marine Organisms.
32649880 2020. Need for Speed: From Human SARS-CoV-2 Samples to Protective and Efficacious Antibodies in Weeks.
32641681 2020. Is hydroxychloroquine beneficial for COVID-19 patients?
32638908 2020. Double-edged sword: Granulocyte colony stimulating factors in cancer patients during the COVID-19 era.
32646869 2020. Challenges in evaluating SARS-CoV-2 vaccines during the COVID-19 pandemic.
32646499 2020. Effect of favipiravir and an anti-inflammatory strategy for COVID-19.
32631373 2020. Clarifying the controversial risk-benefit profile of soluble ACE2 in COVID-19.
32620147 2020. Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series.
32618691 2020. A Centrally Acting Antihypertensive, Clonidine, Sedates Patients Presenting With Acute Respiratory Distress Syndrome Evoked by Severe Acute Respiratory Syndrome-Coronavirus 2.
32640414 2020. Vitamin D deficiency in patients with diabetes and COVID- 19 infection.
32634717 2020. Application of Artificial Intelligence in COVID-19 drug repurposing.
32639233 2020. Concentration-dependent mortality of chloroquine in overdose.
32619390 2020. Shotgun proteomics analysis of SARS-CoV-2-infected cells and how it can optimize whole viral particle antigen production for vaccines.
32615862 2020. Profiles of COVID-19 clinical trials in the Chinese Clinical Trial Registry.
32616599 2020. Potential of regulatory T cell-based therapies in the management of severe COVID-19.
32640331 2020. Analysis of the intricate effects of polyunsaturated fatty acids and polyphenols on inflammatory pathways in health and disease.
32621202 2020. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis.
32638628 2020. Research progress on repositioning drugs and specific therapeutic drugs for SARS-CoV-2.
32622993 2020. Prophylactic (hydroxy)chloroquine in COVID-19: potential relevance for cardiac arrhythmia risk.
32621881 2020. INCIDENCE OF ARRHYTHMIAS AND ELECTROCARDIOGRAPHIC ABNORMALITIES IN SYMPTOMATIC PEDIATRIC PATIENTS WITH PCR POSITIVE SARS-CoV-2 INFECTION INCLUDING DRUG INDUCED CHANGES IN THE CORRECTED QT INTERVAL (QTc).
32641876 2020. Curcumin: a Wonder Drug as a Preventive Measure for COVID19 Management.
32641874 2020. Hydroxychloroquine and Covid-19: A Cellular and Molecular Biology Based Update.
32643111 2020. Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19 Disease.
32640381 2020. Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches.
32642806 2020. Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab.
32645633 2020. An update on antiviral antibody-based biopharmaceuticals.
32645632 2020. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
32634603 2020. COVID-19 Treatment: Close to a Cure? - A Rapid Review of Pharmacotherapies for the Novel Coronavirus.
32646770 2020. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
32639711 2020. CNS Penetration Ability: A Critical Factor for Drugs in the Treatment of SARS-CoV-2 Brain Infection.
32619190 2020. Passive immunization: Paradoxical and traditional method for new pandemic challenge COVID-19.
32648245 2020. COVID-19 and Mesenchymal Stem Cell Treatment; Mystery or Not.
32628223 2020. Very Long-acting Antivirals as Chemovaccines for Preventing Viral Infections.
32640172 2020. Poly(ADP-ribose) Polymerase Inhibition in Acute Lung Injury: A Re-emerging Concept.
32634026 2020. COVID-19 Clinical Trials: Unravelling a Methodological Gordian Knot.
32628535 2020. Regulatory T Cells for Treating Patients With COVID-19 and Acute Respiratory Distress Syndrome: Two Case Reports.
32647027 2020. Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study.
32632035 2020. Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD.
32632034 2020. COVID-19 in paediatric rheumatology patients treated with b/tsDMARDs: a cross-sectional patient survey study.
32632030 2020. Response to: 'COVID-19 in paediatric rheumatology patients treated with b/tsDMARDs: a cross-sectional patient survey study' by Cuceoglu et al.
32620597 2020. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study.
32641296 2020. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
32631826 2020. Clinical trials of repurposed antivirals for SARS-CoV-2.
32639103 2020. Trainee Led Collaboratives, Clinical Trials And New Opportunities In The Covid-19 Era.
32644876 2020. Nutrients in prevention, treatment, and management of viral infections; special focus on Coronavirus.
32646867 2020. Vaccines, convalescent plasma, and monoclonal antibodies for covid-19.
32631851 2020. Urgent call for greater multilateralism and coordination of covid-19 trials.
32631850 2020. Covid-19: research methods must be flexible in a crisis.
32620554 2020. Dexamethasone in the management of covid -19.
32611587 2020. Covid-19: Lopinavir-ritonavir does not benefit hospitalised patients, UK trial finds.
32641344 2020. COVID-19 clinical trials: see it big and keep it simple.
32639062 2020. Serious adverse events with tocilizumab: pharmacovigilance as an aid to prioritize monitoring in COVID-19.
32627226 2020. Potential role of IL-17 blocking agents in the treatment of severe COVID-19?
32645204 2020. Double-bright (CD56bright/CD16bright) NK cell adoptive immunotherapy for SARS-CoV-2.
32621754 2020. COVID-19 pandemic and management of GIMEMA clinical trials: changes and challenges.
32639031 2020. Proteinase-activated receptor 1 (PAR1): A target for repurposing in the treatment of COVID-19?
32640179 2020. Current Therapies Under Investigation for COVID-19.
32633733 2020. Interaction of hydroxychloroquine with SARS-CoV2 functional proteins using all-atoms non-equilibrium alchemical simulations.
32613971 2020. Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection.
32621392 2020. Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalised with COVID-19 are associated with greater disease severity.
32640049 2020. Immune checkpoint inhibition in the era of COVID-19.
32640019 2020. Proposing minimum requirements for announcing clinical trial results during the COVID-19 pandemic.
32628748 2020. Evaluating use cases for human challenge trials in accelerating SARS-CoV-2 vaccine development.
32648959 2020. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
32634894 2020. Smoking in critically ill patients with COVID-19: the Australian experience.
32628049 2020. Analytical Methods on Determination in Pharmaceuticals and Biological Materials of Chloroquine as Available for the Treatment of COVID-19.
32619167 2020. Effect of the Phytochemical Agents Against the SARS-CoV and Selected Some of them for Application to COVID-19: A Mini-Review.
32634080 2020. Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19).
32634079 2020. The role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases.
32628591 2020. Elucidating the Pivotal Role of Immune Players in the Management of COVID-19: Focus on Mesenchymal Stem Cells and Inflammation.
32648845 2020. Therapeutic targets and computational approaches on drug development for COVID-19.
32621718 2020. Shape-based Machine Learning Models for the potential Novel COVID-19 protease inhibitors assisted by Molecular Dynamics Simulation.
32643448 2020. Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Huashi Baidu formula in the treatment of COVID-19.
32632960 2020. Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review.
32629169 2020. Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges.
32616659 2020. BET 2: Hydroxychloroquine in the treatment of COVID-19.
32616658 2020. BET 1: Lopinavir-ritonavir and COVID-19.
32641191 2020. Bacillus Calmette-Guerin vaccination and clinical characteristics and outcomes of COVID-19 in Rhode Island, United States: a cohort study.
32648935 2020. SGLT2 inhibition and COVID-19: The road not taken.
32620680 2020. Do psychotropic drugs used during COVID-19 therapy have an effect on the treatment process?
32631083 2020. Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19.
32643980 2020. Predictor of poor prognosis of COVID-19 patients----liver injury.
32649840 2020. Liver injury in severe COVID-19 infection: current insights and challenges.
32639083 2020. Balancing infection control and frailty prevention during and after the COVID-19 pandemic: Introduction of the NCGG Home Exercise Program for Older People 2020.
32645727 2020. Isopathic Remedy Prepared from Convalescent Plasma as a Therapeutic Option for COVID-19?
32643512 2020. Thinking more about therapy with convalescent plasma for COVID-19 patients.
32633162 2020. Successful Treatment of Covid-19 Associated Cytokine Release Syndrome with Colchicine. A Case Report and Review of Literature.
32643997 2020. Effect of recombinant human granulocyte colony-stimulating factor on lymphocyte subsets in patients with COVID-19.
32615877 2020. Suggestions for Combatting COVID-19 by Natural Means in the Absence of Standard Medical Regimens.
32649272 2020. Combating COVID-19 and Building Immune Resilience: A Potential Role for Magnesium Nutrition?
32643552 2020. Identification of bioactive molecule from Withania somnifera (Ashwagandha) as SARS-CoV-2 main protease inhibitor.
32643550 2020. Potential of NO donor furoxan as SARS-CoV-2 main protease (M(pro)) inhibitors: in silico analysis.
32643529 2020. Natural-like products as potential SARS-CoV-2 M(pro) inhibitors: in-silico drug discovery.
32627715 2020. Screening of phytochemical compounds of Tinospora cordifolia for their inhibitory activity on SARS-CoV-2: an in silico study.
32627689 2020. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.
32619162 2020. Bacterial protein azurin and derived peptides as potential anti-SARS-CoV-2 agents: insights from molecular docking and molecular dynamics simulations.
32619134 2020. Epitope based peptide vaccine against SARS-COV2: an immune-informatics approach.
32618198 2020. Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights.
32643158 2020. Excavating SARS-coronavirus 2 genome for epitope-based subunit vaccine synthesis using immunoinformatics approach.
32643200 2020. Convalescent plasma therapy in patients with COVID-19.
32647045 2020. Hydroxychloroquine and COVID-19: critiquing the impact of disease public profile on policy and clinical decision-making.
32644254 2020. Early use of tocilizumab in the prevention of adult respiratory failure in SARS-CoV-2 infections and the utilization of interleukin-6 levels in the management.
32644224 2020. Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection.
32644208 2020. Erythropoietin Induced Hemoglobin Sub-Unit Beta may Stimulate Innate Immune RNA Virus Pattern Recognition, Suppress Reactive Oxygen Species, Reduce ACE2 Viral Doorway Opening and Neutrophil Extracellular Traps against Covid-19.
32633865 2020. A retrospective review of memantine use and COVID-19-associated mortality from a national database.
32633831 2020. RNA-dependent RNA Polymerase of SARS-CoV-2 as a Therapeutic Target.
32621621 2020. Lopinavir/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: a retrospective matched-pair cohort study.
32617989 2020. Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.


32634602 2020. Corticosteroid therapy for patients with CoVID-19 pneumonia: a before-after study.
32629115 2020. A pharmacological perspective of Chloroquine in SARS-CoV-2 infection.
32619764 2020. Case reports study of the first five patients COVID-19 treated with remdesivir in France.
32634589 2020. Potential effective treatment for COVID-19: systematic review and meta-analysis of the severe infectious disease with convalescent plasma therapy.
32623082 2020. Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19.
32623080 2020. An Observational Cohort Study of Hydroxychloroquine and Azithromycin for COVID-19: (Can't Get No) Satisfaction.
32629817 2020. Influence of Herbal Medicines on HMGB1 Release, SARS-CoV-2 Viral Attachment, Acute Respiratory Failure, and Sepsis. A Literature Review.
32617855 2020. Phylogenetic Analysis and Structural Perspectives of RNA-Dependent RNA-Polymerase Inhibition from SARs-CoV-2 with Natural Products.
32627127 2020. Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic.
32623068 2020. Nucleic Acid Approaches to Antibody-based Therapeutics for COVID-19: A Perspective.
32634126 2020. SARS-CoV-2 viral load and antibody responses: the case for convalescent plasma therapy.
32629768 2020. Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives.
32630746 2020. SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening.
32622963 2020. Mesenchymal stromal cells and their secreted extracellular vesicles as therapeutic tools for COVID-19 pneumonia? ().
32622008 2020. Azithromycin and SARS-CoV-2 infection: where we are now and where we are going.
32636240 2020. BCG vaccine and COVID-19: implications for infection prophylaxis and cancer immunotherapy.
32611687 2020. On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19.
32627442 2020. Convalescent Plasma Therapy in Coronavirus Disease 2019: a Case Report and Suggestions to Overcome Obstacles.
32638109 2020. Mild COVID-19 infection in an NMO patient treated with tocilizumab: a confirmation of anti-IL-6 protective role?
32646487 2020. Evolving geographic diversity in SARS-CoV2 and in silico analysis of replicating enzyme 3CL(pro) targeting repurposed drug candidates.
32635935 2020. Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach.
32631442 2020. Systematic review of the registered clinical trials for coronavirus disease 2019 (COVID-19).
32650019 2020. Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19.
32629788 2020. Calcineurin Inhibitor-Based Immunosuppression and COVID-19: Results from a Multidisciplinary Cohort of Patients in Northern Italy.
32610445 2020. Microbial Natural Products as Potential Inhibitors of SARS-CoV-2 Main Protease (M(pro)).
32634550 2020. Aptamers, the bivalent agents as probes and therapies for coronavirus infections: A systematic review.
32641037 2020. Caspase1/11 signaling affects muscle regeneration and recovery following ischemia, and can be modulated by chloroquine.
32647131 2020. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice.
32648153 2020. The risk of QTc-interval prolongation in COVID-19 patients treated with chloroquine.
32641560 2020. COVID-19 and vitamin D deficiency, a fatal combination?
32645974 2020. SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings.
32619723 2020. Edaravone: A potential treatment for the COVID-19-induced inflammatory syndrome?
32622723 2020. Chinese herbal medicine for coronavirus disease 2019: A systematic review and meta-analysis.
32629137 2020. Ultraviolet-based Biophotonic Technologies and COVID-19.
32641511 2020. Discovery of potent thrombin inhibitors from a protease-focused DNA-encoded chemical library.
32621829 2020. Letter to the editor regarding "Lack of supporting data make the risks of a clinical trial of radiation therapy as a treatment for COVID-19 pneumonia unacceptable".
32638884 2020. Primum non nocere - Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?
32616763 2020. A candidate multi-epitope vaccine against SARS-CoV-2.
32638647 2020. Alternative management of Covid-19 infection.
32636116 2020. First case of convalescent plasma transfusion in a child with COVID-19-associated severe aplastic anemia.
32645478 2020. Hydroxychloroquine safety: A meta-analysis of randomized controlled trials.
32629139 2020. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France".
32635353 2020. Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation During Acute Respiratory Distress: A Case Report and Literature Review.
32640619 2020. Prospects and Challenges in the Development of Universal Influenza Vaccines.
32635180 2020. Immunoinformatic Analysis of T- and B-Cell Epitopes for SARS-CoV-2 Vaccine Design.
32621841 2020. Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2.
32629804 2020. Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review.
32620700 2020. Low Dose Radiation to COVID-19 Patients to Ease the Disease Course and Reduce the Need of Intensive Care.
32623965 2020. Are we aware of potential interactions between drugs used in lung cancer and drugs used in the treatment of COVID-19?
32628262 2020. The Development of COVID-19 Vaccines: Safeguards Needed.
32628244 2020. Developing a SARS-CoV-2 Vaccine at Warp Speed.
32614442 2020. Evolution of Altered Sense of Smell or Taste in Patients With Mildly Symptomatic COVID-19.
32613691 2020. Editorial - Nutritional Status Affects COVID-19 Patient Outcomes.
32613660 2020. Evaluation of Nutritional Risk and its Association With Mortality Risk in Severe and Critically Ill COVID-19 Patients.
32619276 2020. Low dose radiation as a treatment for COVID-19 pneumonia: a threat or real opportunity?
32619669 2020. Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease.
32633860 2020. Safety of Plasma Infusions in Parkinson's Disease.
32649078 2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.
32649077 2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.
32649076 2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.
32649075 2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.
32649074 2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.
32643410 2020. Bioactive compounds from marine resources against novel corona virus (2019-nCoV): in silico study for corona viral drug.
32636505 2020. COVID-19 platform trial delivers.
32623442 2020. Going back in time for an antibody to fight COVID-19.
32645305 2020. Golden Anniversary of the Nicotinic Receptor.
32618794 2020. Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19).
32615642 2020. Is povidone-iodine mouthwash effective against SARS-CoV-2? First in vivo tests.
32613637 2020. Naringenin, a flavanone with antiviral and anti-inflammatory effects: A promising treatment strategy against COVID-19.
32648294 2020. COVID-19: Phylogenetic approaches may help in finding resources for natural cure.
32647056 2020. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19).
32648313 2020. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
32614102 2020. Using heat to kill SARS-CoV-2.
32646977 2020. Can interferons stop COVID-19 before it takes hold?
32649367 2020. Potential Immunotherapeutic Targets For Hypoxia Due to COVI-FLU.
32619318 2020. COVID-19 drug repurposing: Summary statistics on current clinical trials and promising untested candidates.
32627216 2020. Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation.
32639598 2020. SARS-CoV2 and immunosuppression: a double-edged sword.
32629531 2020. Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib.
32614684 2020. Review of the SARS-CoV-2 in Wuhan and Analysis as Well as Prediction of Therapeutic Drugs.


32388537 2020. Designing of improved drugs for COVID-19: Crystal structure of SARS-CoV-2 main protease M(pro).
32532959 2020. The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin.
32423553 2020. Angiotensin converting enzyme: A review on expression profile and its association with human disorders with special focus on SARS-CoV-2 infection.
32531235 2020. Role of the GTNGTKR motif in the N-terminal receptor-binding domain of the SARS-CoV-2 spike protein.
32430279 2020. Gut microbiota and Covid-19- possible link and implications.
32416259 2020. On the interactions of the receptor-binding domain of SARS-CoV-1 and SARS-CoV-2 spike proteins with monoclonal antibodies and the receptor ACE2.
32558150 2020. Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation.
32585135 2020. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.
32546195 2020. Micronutrient status of COVID-19 patients: a critical consideration.
32559343 2020. Rationale for targeting Complement in COVID-19.
32543705 2020. Evolutionary relationships and sequence-structure determinants in human SARS coronavirus-2 spike proteins for host receptor recognition.
32592394 2020. A role for selenium-dependent GPX1 in SARS-CoV-2 virulence.
32590326 2020. Pulmonary surfactant itself must be a strong defender against SARS-CoV-2.
32562814 2020. Statins and other drugs: Facing COVID-19 as a vascular disease.
32424591 2020. COVID-19, acute respiratory distress syndrome (ARDS), and hyperbaric oxygen therapy (HBOT): what is the link?
32598884 2020. Alterations in Fecal Fungal Microbiome of Patients With COVID-19 During Time of Hospitalization until Discharge.
32481719 2020. The Role of MicroRNA in the Airway Surface Liquid Homeostasis.
32534506 2020. Bradykinin as a Probable Aspect in SARS-Cov-2 Scenarios: Is Bradykinin Sneaking out of Our Sight?
32600316 2020. The cholinergic anti-inflammatory pathway alleviates acute lung injury.
32537478 2020. Airways Expression of SARS-CoV-2 Receptor, ACE2, and TMPRSS2 Is Lower in Children Than Adults and Increases with Smoking and COPD.
32595361 2020. Gut-lung axis and dysbiosis in COVID-19.
32591496 2020. Door to the cell for COVID-19 opened, leading way to therapies.
32602262 2020. Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series.
32555145 2020. Targeting the entry step of SARS-CoV-2: a promising therapeutic approach.
32594085 2020. Early Hemoperfusion for Cytokine Removal May Contribute to Prevention of Intubation in Patients Infected with COVID-19.
32582574 2020. ACE2, Much More Than Just a Receptor for SARS-COV-2.
32545271 2020. Relative Abundance of SARS-CoV-2 Entry Genes in the Enterocytes of the Lower Gastrointestinal Tract.

32593832 2020. Why is SARS-CoV-2 infection more severe in obese men? The gut lymphatics - Lung axis hypothesis.


32573788 2020. Elucidation of Cellular Targets and Exploitation of the Receptor Binding Domain of SARS-CoV-2 for vaccine and monoclonal antibody synthesis.
32551652 2020. Critical Differences Between the Binding Features of the Spike Proteins of SARS-CoV-2 and SARS-CoV.
32551648 2020. The Discovery of a Putative Allosteric Site in the SARS-CoV-2 Spike Protein Using an Integrated Structural/Dynamic Approach.
32571797 2020. Identification of common deletions in the spike protein of SARS-CoV-2.
32606248 2020. Genomic discovery of an evolutionarily programmed modality for small-molecule targeting of an intractable protein surface.
32602627 2020. Angiotensin-converting enzyme 2: The old door for new severe acute respiratory syndrome coronavirus 2 infection.


32417594 2020. Supplements for COVID-19: A modifiable environmental risk.

Von „http://coviki.org/cov/index.php?title=Candidate_Compounds_Covid19&oldid=3605“
Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis